検索結果 - Ulrika S. H. Simonsson

Individualized Dosing With High Inter-Occasion Variability Is Correctly Handled With Model-Informed Precision Dosing-Using Rifampicin as an Example 著者: Lina Keutzer, Ulrika S. H. Simonsson

Connect to this object online.

Finding the right hazard function for time‐to‐event modeling: A tutorial and Shiny application 著者: Rob C. VanWijk, Ulrika S. H. Simonsson

Connect to this object online.

A modeling‐based proposal for safe and efficacious reintroduction of bedaquiline after dose interruption: A population pharmacokinetics study 著者: Lina Keutzer, Yasamin Akhondipour Salehabad, Lina Davies Forsman, Ulrika S. H. Simonsson

Connect to this object online.

Phase III dose selection of marzeptacog alfa (activated) informed by population pharmacokinetic modeling: A novel hemostatic drug 著者: Alan Faraj, Tom Knudsen, Shraddha Desai, Linda Neuman, Grant E. Blouse, Ulrika S. H. Simonsson

Connect to this object online.

Derivation and Clinical Utility of Safety Targets for Linezolid-Related Adverse Events in Drug-Resistant Tuberculosis Treatment 著者: Lina Keutzer, Laurynas Mockeliunas, Marieke G. G. Sturkenboom, Mathieu S. Bolhuis, Onno W. Akkerman, Ulrika S. H. Simonsson

Connect to this object online.

Seasonal influence on respiratory tract infection severity including COVID‐19 quantified through Markov Chain modeling 著者: Rob C. vanWijk, Laurynas Mockeliunas, Caryn M. Upton, Jonathan Peter, Andreas H. Diacon, Ulrika S. H. Simonsson

Connect to this object online.

Model‐informed pediatric dose selection of marzeptacog alfa (activated): An exposure matching strategy 著者: Alan Faraj, Rob C. vanWijk, Linda Neuman, Shraddha Desai, Grant E. Blouse, Tom Knudsen, Ulrika S. H. Simonsson

Connect to this object online.

Model-Informed Precision Dosing of Linezolid in Patients with Drug-Resistant Tuberculosis 著者: Laurynas Mockeliunas, Lina Keutzer, Marieke G. G. Sturkenboom, Mathieu S. Bolhuis, Lotte M. G. Hulskotte, Onno W. Akkerman, Ulrika S. H. Simonsson

Connect to this object online.

Standards for model-based early bactericidal activity analysis and sample size determination in tuberculosis drug development 著者: Laurynas Mockeliunas, Alan Faraj, Rob C. van Wijk, Caryn M. Upton, Gerben van den Hoogen, Andreas H. Diacon, Ulrika S. H. Simonsson

Connect to this object online.

Pharmacokinetics and pharmacodynamics of anti-tuberculosis drugs: An evaluation of in vitro, in vivo methodologies and human studies 著者: Jan-Willem C. Alffenaar, Jan-Willem C. Alffenaar, Jan-Willem C. Alffenaar, Jurriaan E. M. de Steenwinkel, Andreas H. Diacon, Ulrika S. H. Simonsson, Shashikant Srivastava, Sebastian G. Wicha

Connect to this object online.

Combined quantitative tuberculosis biomarker model for time-to-positivity and colony forming unit to support tuberculosis drug development 著者: Rami Ayoun Alsoud, Robin J. Svensson, Elin M. Svensson, Elin M. Svensson, Stephen H. Gillespie, Martin J. Boeree, Andreas H. Diacon, Rodney Dawson, Rodney Dawson, Rob E. Aarnoutse, Ulrika S. H. Simonsson

Connect to this object online.

Machine Learning and Pharmacometrics for Prediction of Pharmacokinetic Data: Differences, Similarities and Challenges Illustrated with Rifampicin 著者: Lina Keutzer, Huifang You, Ali Farnoud, Joakim Nyberg, Sebastian G. Wicha, Gareth Maher-Edwards, Georgios Vlasakakis, Gita Khalili Moghaddam, Elin M. Svensson, Michael P. Menden, Ulrika S. H. Simonsson, on behalf of the UNITE4TB Consortium

Connect to this object online.